Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment

Clinical Cancer Research

Volumn 11, Issue 2 I, 2005, Pages 743-750

  Ansiaux, Réginald ^a   Baudelet, Christine ^a   Jordan, Bénédicte F ^a   Beghein, Nelson ^a   Sonveaux, Pierre ^a   De Wever, Julie ^a   Martinive, Philippe ^a   Grégoire, Vincent ^a   Feron, Olivier ^a   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIBODY LABELING; ARTICLE; CANCER RADIOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; LASER DOPPLER FLOWMETRY; MOUSE; NONHUMAN; OXIMETRY; OXYGEN TENSION; PERFUSION; PERMEABILITY; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; TISSUE OXYGENATION; TISSUE PRESSURE; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CONTRAST MEDIA; ELECTRON SPIN RESONANCE SPECTROSCOPY; FIBROSARCOMA; GADOLINIUM DTPA; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C3H; OSMOTIC PRESSURE; OXYGEN; OXYGEN CONSUMPTION; RADIATION TOLERANCE; THALIDOMIDE; X-RAYS;

EID: 19944426756     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947-70.
3. Konerding MA, Van Ackern C, Fait E, Steinberg F, Streffer C. Morphological aspects of tumor angiogenesis and microcirculation. In: Molls M, Vaupels P, editors. Blood perfusion and microenvironment of human tumors. Berlin: Springer-Verlag; 1998. p. 5-17.
4. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003;8:396-403.
5. Dewhirst MW, Kimura H, Rehmus SW, et al. Microvascular studies on the origins of perfusion-limited hypoxia. Br J Cancer Suppl 1996;27:247-51.
6. Burke PA, DeNardo SJ. Antiangiogenic agents and their promising potential in combined therapy. Crit Rev Oncol Hematol 2001;39:155-71.
7. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7: 987-9.
8. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
9. Tzuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. VEGF modulation by targeting HIF-1α > HRE > VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000;60:6248-52.
10. Kadambi A, Carreira CM, Yun C, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment. Cancer Res 2001;61:2404-8.
11. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60:4556-60.
12. Lee C, Heijn M, Di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
13. Bello L, Carrabba G, Giussani C, et al. A. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
14. Shalinsky DR, Brekken J, Zou H, et al. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cancer lung cancer tumors: single agent and combination chemotherapy studies. Clin Cancer Res 1999;5:1905-17.
15. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effect of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394:287-91.
16. Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-9.
17. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
18. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-5.
19. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
20. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Völcker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236:461-6.
21. Verheul HMW, Panigrahy D, Yuan J, D'Amato RJ. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer 1999;79:114-8.
22. Von Moos R, Stolz R, Cerny T, Gillessen S. Thalidomide: from tragedy to promise. Swiss Med Wkly 2003;133:77-87.
23. Volpe JP, Hunter N, Basic I, Milas L. Metastatic properties of murine sarcomas and carcinomas. I. Positive correlation with lung colonization and lack of correlation with s.c. tumor take. Clin Exp Metastasis 1985; 3:281-94.
24. Jordan BF, Baudelet C, Gallez B. Carbon-centered radicals as oxygen sensors for in vivo electron paramagnetic resonance: screening for an optimal probe among commercially available charcoals. Magn Reson Mater Phys Med Biol 1998;7:121-9.
25. Gallez B, Jordan BF, Baudelet C, Misson PD. Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry. Magn Reson Med 1999;42: 627-30.
26. Jordan BF, Misson P, Demeure R, Baudelet C, Beghein N, Gallez B. Changes in tumor oxygenation/perfusion induced by the NO donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int J Radiat Oncol Biol Phys 2000; 48:565-70.
27. Sersa G, Cemazar M, Miklavcic D, Chaplin, DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 1999;19:4017-22.
28. Baudelet C, Gallez B. Cluster analysis of BOLD fMRI time series in tumors to study the heterogeneity of hemodynamic response to treatment. Magn Reson Med 2003;49:985-90.
29. Su MY, Jao JC, Nalcioglu O. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI. Magn Reson Med 1994;32:714-24.
30. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-4.
31. Lee I, Boucher Y, Jain RK. Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. Cancer Res 1992;52:3237-40.
32. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of HS Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-4.
33. Fenton BM, Paoni SF, Grimwood BG, Ding I. Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. Int J Radiat Oncol Biol Phys 2003;57: 1038-46.
34. Teicher BA, Holden SA, Ara G, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 1995;61:732-7.
35. Teicher BA, Dupis N, Kusomoto T, et al. Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Investig 1995;2:269-76.
36. Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 1998;18:2567-73.
37. Drevs J, Muller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015-22.
38. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999;43:1111-23.
39. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993;73:1-78.
40. 51Cr-EDTA. Int J Cancer 2000;86:636-43.
41. Kinuya S, Kawashima A, Yokoyama K, et al. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med 2002;43:1084-9.
42. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000;6:971-8.
43. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61:39-44.
44. Moreira AL, Friedlander DR, Shif B, Kaplan G, Zagzag D. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. J Neurooncol 1999;43:109-14.
45. Gutman M, Szold A, Ravid A, Lazauskas T, Merimsky O, Klausner JM. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo. Anticancer Res 1996;16:3673-7.
46. Minchinton AI, Fryer KH, Wendt KR, Clow KA, Hayes MM. The effect of thalidomide on experimental tumors and metastases. Anticancer Drugs 1996;7:339-43.
47. Belo AV, Ferreira MA, Bosco AA, Machado RD, Andrade SP. Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation 2001;25:91-6.